Pure Global AI
NCT06351384Not yet recruiting

Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform

Early Detection and Risk Stratification of Colorectal Cancer Based on miRNA Platform: a Prospective, Pilot Study
Sir Run Run Shaw HospitalClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Colorectal Cancer
Drug/Device/Intervention
miRNA detection test
Study type
Observational
Intervention type
device
Sponsor & location
Primary sponsor
Sir Run Run Shaw Hospital
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Dec 31, 2025
Enrollment
600 participants
Primary outcome

Correlation between post-surgery 1 month MRD status and recurrence-free survival (RFS) in colorectal patients

Summary

This is a prospective, observational cohort study to establish the minimal residual disease
 (MRD) model for predicting relapse risk and identifying disease recurrence in patients with
 colorectal adenocarcinoma based on the miRNA platform.
 
 Blood miRNA markers will be evaluated. The study will enroll approximately 600 participants,
 including participants with malignancies or benign diseases, and healthy participants.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Descending colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06351384
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06351384 through Pure Global AI's free database. This phase not specified trial is sponsored by Sir Run Run Shaw Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.